Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$150.66 USD

150.66
15,009,671

-1.89 (-1.24%)

Updated Aug 24, 2026 04:03 PM ET

After-Market: $151.24 +0.58 (0.38%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (160 out of 247)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate

by Zacks Equity Research

Merck and Daiichi Sankyo begin dosing in the phase III HERTHENA-Breast04 study on patritumab deruxtecan in certain breast cancer patients.

Kinjel Shah headshot

Can Pfizer's Cost Cuts and New Drugs Offset Upcoming Headwinds?

by Kinjel Shah

Pfizer braces for patent losses, IRA pressure and COVID uncertainty, but cost cuts and key drugs may still support profit growth.

Kanishka Das headshot

Will Weak Gardasil Sales Continue to Be a Drag on MRK's Top Line?

by Kanishka Das

Merck halts Gardasil shipments in China after weak demand hurts sales, with declines also seen in Japan.

Ekta Bagri headshot

Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?

by Ekta Bagri

The FDA approval to expand Exelixis' Cabometyx into neuroendocrine tumors is witnessing encouraging uptake and boosting investor focus.

Zacks Equity Research

IOVA Stock Drops 6% on $350M Common Stock Offering

by Zacks Equity Research

Iovance shares slid 6% after unveiling a $350 million stock offering, raising dilution concerns while funding growth plans for Amtagvi and its pipeline.

Ekta Bagri headshot

Exelixis vs. Merck: Which Oncology Stock Is a Better Pick as of Now?

by Ekta Bagri

EXEL rides on Cabometyx momentum and pipeline gains, while MRK leans on Keytruda dominance and a diverse portfolio for growth.

Kinjel Shah headshot

ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth

by Kinjel Shah

AbbVie's oncology sales climbed 4.2% in H1 2025 as new drugs offset Imbruvica declines, strengthening its long-term growth outlook.

Zacks Equity Research

Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks Equity Research

MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer

by Zacks Equity Research

Merck's ifinatamab deruxtecan wins FDA Breakthrough Therapy status for treating adults with extensive-stage small cell lung cancer.

Kinjel Shah headshot

Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?

by Kinjel Shah

Pfizer's oncology portfolio, boosted by Seagen and strong drug sales, fuels Q2 growth and positions the company for future cancer treatment gains.